Publications by authors named "Feng Roger Luo"

Claim this Profile
A
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Yi-Chen Zhang, Zhi-Hong Chen, Xu-Chao Zhang, Chong-Rui Xu, Hong-Hong Yan, Feng Roger Luo

EBioMedicine· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.
Feng Roger Luo, Jian Ding, Helen X Chen, Hao Liu, Man-Cheong Fung

Chin J Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).
Andres Forero-Torres, Jatin Shah, Tina Wood, James Posey, Ronda Carlisle, Feng Roger Luo

Cancer Biother Radiopharm· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Feng Roger Luo, Yu Chen Barrett, Zheng Yang, Amy Camuso, Kelly McGlinchey

Cancer Chemother Pharmacol· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.
Robert Wild, Krista Fager, Christine Flefleh, David Kan, Ivan Inigo, Feng Roger Luo

Mol Cancer Ther· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis